Drug intelligence / Profile preview

ZanthoSyn

Development stage: Unknown
Lead developer: Cardax
Modality: Small Molecules
Administration: Oral

Overview

ZanthoSyn is a synthetic astaxanthin dietary supplement developed and marketed by Cardax Pharmaceuticals for the support of inflammatory health. The product utilizes AstaSana™, a high-purity synthetic astaxanthin ingredient manufactured by DSM Nutritional Products, which is designed for superior absorption compared to traditional natural sources. ZanthoSyn exerts its effects at the cellular and mitochondrial levels, promoting anti-inflammatory activity and antioxidant protection without inhibiting normal physiological functions. It is commercially available and positioned for the improvement of healthspan and lifespan, specifically targeting joint and muscle function, cognitive performance, and cardiovascular health.

Brand names: ZanthoSyn
Other names: astaxanthin dietary supplement

Beyond the preview

Go deeper on ZanthoSyn.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZanthoSyn.

Explore the full profile